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Cutaneous T-cell lymphomas (CTCL) are mainly comprised of two variants: mycosis fungoides (MF) with CD4 þ tumor cells confined to the skin and the leukemic Sé zary syndrome with tumor cell spread to the blood. In this study, we investigated cutaneous expression of the regulatory T-cell (T reg ) marker FOXP3 in 30 þ T cells were also markedly reduced in the CD4 þ population within the peripheral blood of Sé zary patients compared to controls as determined by fluorescence-activated cell sorter, quantitative PCR and functional analyses. The data support the conclusion that the neoplastic cells in CTCL do not express the T reg marker FOXP3. Our data also identify Sé zary syndrome as, to our knowledge, the first reported neoplastic disease with a clear reduction in T reg numbers within the CD4 þ population. This lack of T reg
Introduction
Cutaneous T-cell lymphomas (CTCL) represent a heterogeneous group of rare lymphoproliferative disorders of skin homing T cells with an estimated annual incidence of 0.65/100 000. 1 The most common variant, mycosis fungoides (MF), is confined to the skin and characterized by patches, plaques and/or tumors occurring at different stages of the disease. 2 In contrast, the more aggressive Sézary syndrome is defined by erythroderma, generalized lymphadenopathy and circulating tumor cells in the peripheral blood (41000 cells/mm 3 ). 3 Cutaneous T-cell lymphomas represent monoclonal proliferations of CD4 þ T cells that produce Th2 cytokines 4 and show resistance to interferon-g. 5 One study examined the CD25 expression of CTCL tumor cells in 17 CTCL patients showing a median of 20% CD25 þ tumor cells in skin samples, which was comparable to skin specimens from patients with chronic dermatitis (5-20%). 6 Unfortunately, detailed results on CD25 expression in MF and Sézary patients were not supplied, as all patients were summarized in the CTCL group. Another group could show that tumor cells of Sézary patients failed to upregulate CD25 following incubation with a-CD3 antibody. 7 Advanced CTCL patients often show features of immunosuppression with a fatal outcome owing to an increased susceptibility to various infections. This immunosuppression could be explained by either a replacement of reactive CD4 þ and CD8 þ cells by the tumor or by an immunosuppressive nature of the tumor. The latter hypothesis is supported by a recent study by Berger et al. 8 suggesting that CTCL is a malignant proliferation of regulatory T cells (T reg ). This group demonstrated in an in vitro model that under certain circumstances, CTCL tumor cells could express FOXP3, currently the best marker to identify T reg . 9 Such FOXP3 þ CTCL cells show characteristics of T reg function: for example, production of interleukin-10 and transforming growth factor-b as well as suppression of effector T-cell responses. 9, 10 Another group suggested that adult T-cell leukemia/lymphoma could possibly originate from human T lymphotropic virus type-1-infected T reg . 11 In healthy individuals, T reg are usually rare, representing only less than 5% of peripheral blood mononuclear cells, and can be identified by very high CD25 expression (CD25 high ) and expression of the transcriptional repressor scurfin (FOXP3). 9, 12, 13 However, it remains unclear if FOXP3 þ CTCL cells exist in vivo and if FOXP3 might serve as a CTCL tumor cell marker. We analyzed skin samples from 30 CTCL patients including MF, Sézary syndrome, small-/medium-sized pleomorphic CTCL and lymphomatoid papulosis for the presence of FOXP3 þ cells. FOXP3, CD4, CD25 and CD95 expression was further analyzed in peripheral blood of patients with Sézary syndrome together with apoptosis assays of fluorescence-activated cell-sorted (FACS) Sézary CD4 þ T cells.
Patients, materials and methods

Patients
Thirty patients with different types of CTCL diagnosed according to the WHO-EORTC classification of cutaneous lymphomas 1 and the criteria of the international society of cutaneous lymphomas 3 were included in the study ( Table 1) . As controls, we investigated skin biopsy specimens from patients with chronic dermatitis (n ¼ 15), psoriasis (n ¼ 3), atopic dermatitis (n ¼ 10) and blood samples from healthy donors (n ¼ 8). Informed consent was obtained from all subjects before inclusion. The study was conducted according to the ethical guidelines at our institution and the Helsinki Declaration, and approved by the ethics committee II of the Ruprecht-KarlsUniversity of Heidelberg, Germany.
Histology and immunohistochemistry
Skin biopsies were taken at first presentation of the patients before the onset of treatment and were fixed in formalin. Hematoxylin and eosin, CD4 (clone 1F6, Novocastra, Newcastle upon Tyne, UK) and CD25 (clone 4C9, Dianova, Hamburg, Germany) stainings were performed as described. 14 For FOXP3 staining, we used 4 mm sections, FOXP3 IgG1 antibody (Ab) 236A/E7 (AHB, GR) or mouse IgG1 isotype control (Dako, Glostrup, Denmark) and followed the published protocol. 15 All specimens were blinded and analyzed by two independent investigators (CDK, NP) as described. 16 Each investigator evaluated the proportion of positively stained cells, expressed as a fraction of the total lymphocytic infiltrate, and the percentage of CD4 þ and FOXP3 þ cells for each case was calculated from the values of six different areas.
Cell isolation and sorting
Peripheral blood lymphocytes were obtained from healthy individuals and Sézary patients and separated by Ficoll gradient centrifugation. After staining with phycoerythrin-labeled a-CD25 Ab (Miltenyi Biotech, Auburn, CA, USA) and fluorescein isothiocyanate-labeled a-CD4 Ab (BD Pharmingen, Heidelberg, Germany),
þ CD25 high (T reg ) cells were sorted with a FACS-Divat cell sorter (BD Biosciences) as described. 13 
Cell surface staining
Cells were stained with PE-labeled a-CD25, PE-Cy5-or FITClabeled a-CD4 Ab and FITC-labeled aCD95 Ab or their respective isotype control Ab and analyzed with a FACScan cytometer with at least 10 000 cells counted. 13 The agonistic monoclonal aCD95 Ab (aApo-1) was purified from hybdridoma supernatants by Protein A (Sigma-Aldrich, St Louis, MO, USA) affinity purification. 17 
Cell culture and cytotoxicity assays
Freshly isolated T cells were cultured in IL-2 (100 IU) containing ex vivo-15t medium (Cambrex, Verviers, Belgium) supplemented with 1% Glutamax (Invitrogen, Karlsruhe, Germany). For apoptosis induction, T cells were stimulated with a 1:10 dilution of a leucine zipper-tagged CD95 ligand (CD95L). 17, 18 Annexin V Alexa Fluor 488 was purchased from Molecular Probes (Eugene, OR, USA) and propidium iodide (PI) was obtained from Sigma-Aldrich (St Louis, MO, USA). Unstimulated cells were incubated with CD95L-free control medium yielding spontaneous apoptosis of 15-30% in 20 h. Cell death was assessed by annexin V/PI costaining and forward-to-sideward-scatter profile. Specific cell death was calculated as described previously:
17 Table 1 Patient characteristics regarding clinical data, histological evaluation of the skin biopsies and molecular biological data 
RNA preparation and quantitative reverse transcription-PCR
Total RNA was isolated using the Absolutely RNA Microprep kit (Stratagene, Heidelberg, Germany) and cDNA was prepared using random oligo(dT) primers (Invitrogen). 13 FOXP3 mRNA expression was quantified by detection of incorporated SYBR s Green using the ABI Prism 5700 sequence detector system (Applied Biosystems, Foster City, CA, USA). The relative expression level was determined by normalization to glyceraldehyde phosphate dehydrogenase with results presented as fold expresssion of T eff mRNA levels. 
Statistical analysis
Data are presented as individual values and as median. The Wilcoxon signed-rank test was used to compare the skin infiltrates of the different patient groups. The test was considered significant when P is less than 0.05.
Results and discussion
FOXP3 staining of paraffin-embedded lymphoid tissues and skin biopsies
In order to identify FOXP3 þ T reg , we first established a FOXP3 staining protocol using various paraffin-embedded lymphoid tissues, for example, tonsils and sorted CD4 þ CD25 high cells (T reg ) from the peripheral blood of healthy donors. Figure S1) . To exclude nonspecific crossreactivity of the FOXP3 Ab with different cells and structures present in the skin, we analyzed normal skin sections, which were all negative (data not shown). The mouse IgG1 isotype control Ab gave negative results in all experiments (data not shown and Figures 1e and j) . This allowed specific detection of FOXP3 þ T reg in paraffin-embedded skin samples as recently shown for other lymphoid tissues. 15 
Cutaneous FOXP3 expression in various types of cutaneous T-cell lymphomas
In this study, we have investigated the presence of FOXP3 þ cells in the skin of 30 patients with MF, rare variants of CTCL and Sézary syndrome ( Table 1 ). The diagnosis was based on the clinical features, histology, immunohistochemistry and molecular studies of TCR rearrangement. In all skin specimens, the lymphocytic infiltrate was predominated by CD3 þ T cells mixed with only single CD20 þ B cells (data not shown). With the exception of three patients, a monoclonal T-cell population could be demonstrated in the skin by either TCR-b or TCR-g rearrangement, which is in accordance with other studies (Table 1) . 19, 21, 22 In patients with MF, the cutaneous lymphomononuclear cell infiltrate was primarily found in the upper dermis, predominated 
by CD4
þ cells with a median of 61719% of total leukocytes (Table 1 and Figures 1a, b and 2a) . Only a minority of CD8 þ cells ranging from o5 to 30% of the lymphocytic skin infiltrate were seen in the skin samples (Table 1 ). FOXP3 þ (n ¼ 16) and CD25 þ (n ¼ 4) cells were readily detected within the dermal infiltrate of MF skin samples (23712 and 2375%, respectively), whereas staining with the isotype control IgG1 antibody was negative (Supplementary Figure S1 and Figures 1c, d and 2a) . FOXP3 is expressed on CD4 þ cells 23 and we found a median of 43% of CD4 þ cells expressing FOXP3 by calculating the percentage of FOXP3 þ cells of all CD4 þ cells for each skin specimen investigated (Figure 2d) . By morphological criteria, these CD4 þ FOXP3 þ cells are small in size and do not look like typical MF tumor cells. In rare CTCL types, we found an almost identical distribution of FOXP3 þ (n ¼ 6) and CD25 þ (n ¼ 1) cells as in MF (Table 1 and Figures 2c and d) . This is in concordance with recent observations in other tumor entities also showing enhanced T reg numbers in the tumor mass 23 or the draining lymph node of malignant melanoma. 24 In patients with Sézary syndrome, the cutaneous infiltrate was also primarily composed of CD4 þ cells (52724% of leukocytes) (Figures 1f, g  and 2b) . However, FOXP3 þ (n ¼ 7) and CD25 þ (n ¼ 3) cells were similarly rare within the dermal infiltrate of Sézary skin samples (975 and 1073% of leukocytes, respectively). Most of the FOXP3 þ cells were also CD25 þ , as demonstrated by double staining (Figures 1k and l) . However, a few cells within the cutaneous infiltrate were CD25 þ and FOXP3 À , and possibly represent activated T cells. 25 We conclude that FOXP3 expression is much more reliable for the detection of T reg than CD25. Overall, only 16% of CD4 þ cells expressed FOXP3 in Sézary syndrome compared to 43% in MF (Po0.05) (Figures 1g,  h and 2b, d) . Interestingly, FOXP3
þ cell numbers in a given patient were remarkably constant over time in MF (no. 11), Sézary syndrome (no. 26) and one patient with small-/mediumsized pleomorphic CTCL (no. 2) when investigated at multiple time points (Supplementary Figure S2A) .
In control patients with chronic dermatitis and psoriasis (n ¼ 18) and atopic dermatitis (n ¼ 10), we obtained similar high ). In contrast, human blood from healthy controls usually contains less than 5% T reg and from patients with atopic dermatitis 7%. 13, 30 The factors governing this accumulation are not clear yet. Further investigations will clarify whether T reg are dysfunctional in inflammation as shown for psoriasis 26 and multiple sclerosis 31 or if the sustained immune response overcomes the suppressive capability of T reg . In cancer, increased numbers of T reg probably contribute to immune suppression; conversely, depletion of T reg can facilitate tumor rejection.
23,32
Characterization of FOXP3 þ cells in the blood of Sézary patients
The suggestion that CTCL is a malignant proliferation of T reg 8 is consistent with our observation of high T reg numbers in the skin of MF and rare types of CTCL but in contrast with the specifically low FOXP3
þ cell numbers seen in Sézary syndrome. A possible explanation might be a shift of the tumor load from the skin to the blood in the leukemic variant of CTCL. Therefore, we investigated the status of T reg in the blood of patients with Sézary syndrome. T reg can be identified by a very high CD25 expression in blood. We found that CD4 þ CD25 high cells were markedly reduced in all patients with Sézary syndrome compared with healthy controls (Table 2 and Figures 3a and b) . Multiple timepoint analyses in one Sézary patient (no. 24) showed consistently low numbers of CD4 þ CD25 high cells during the course of the disease (Supplementary Figure S2B) . Further sorted CD25 þ cells (combined CD25 int and CD25 high cells) showed much lower levels of FOXP3 mRNA than in healthy controls (Figure 3c ). This indicates a loss of T reg in the CD4 þ CD25 þ cell pool of Sézary patients. Other sites of inflammation or tumor cell accumulation in our Sézary patients were excluded by computer tomography scans. We have recently shown that CD95 expression and sensitivity to CD95L-induced apoptosis is a unique feature of T reg within the CD4 þ cell population. 13 In contrast, the CD25 þ cells of Sézary patients only displayed intermediate CD95 receptor expression rates and intermediate sensitivities to CD95L-induced apoptosis (Figures 4a and b) . Thus, blood and skin of Sézary patients contain very few cells with characteristics of T reg . Furthermore, the four CTCL lines (HH, Hut78, Myla, Seax) tested in our lab did not show specific nuclear FOXP3 staining and had no FOXP3 mRNA expression (data not shown). In Sézary syndrome, increasing CD4 þ tumor cell numbers of up to 95% of the total leukocytes probably displace T reg . In the majority of our Sézary syndrome patients, there is also a marked reduction of CD8 þ cells seen in the peripheral blood and in the skin. All skin specimens from Sézary patients with very low numbers of FOXP3 þ cells also had low numbers of CD8 þ cells (Table 1 ). This strongly indicates that expansion of the CD4 þ tumor cell population reduces the relative numbers of CD8 cells and T reg . Interestingly, T reg do not accumulate, as seen for various malignancies. 23, 24 These data also provide convincing evidence that the tumor cells do not express FOXP3. In line with this interpretation, preliminary data demonstrate a polyclonal TCR rearrangement in FACS-sorted CD4 þ CD25 high (T reg gate) cells of patients with Sézary syndrome (data not shown). As we did not detect a dominant T-cell clone within this cell fraction, these data speak against the presence of tumor cells within the CD25 high T reg population. Furthermore, Sézary tumor cells do not express CD25. 7 Nevertheless, as there is no unique CTCL tumor cell marker available, although unlikely, we cannot exclude the possibility that a few tumor cells have gained FOXP3 expression.
Conclusion
Our data collectively suggest that CTCL tumor cells are not of T reg origin. Rather the increased numbers of FOXP3 þ cells denotes an accumulation of T reg in indolent CTCL (MF). This conclusion is also supported by the fact that inflammatory skin diseases accumulate similar numbers of T reg in the skin. One may speculate that T reg not only suppress the anti-tumor immune response, but also have the potential to suppress tumor growth in MF. Thus, the lack of T reg in Sézary syndrome might account for the more aggressive course seen in these patients. Furthermore, preliminary results have demonstrated a trend towards a worse outcome for patients with rare variants of CTCL and MF with lower numbers of T reg found in their skin lesions (data not shown). Finally, we would like to stress that to the best of our knowledge Sézary syndrome is the first reported malignancy with a clear reduction in T reg cell numbers within the CD4 þ population. Therapeutically, this loss of T reg could possibly be counteracted by extracorporeal photopheresis, which was recently shown to induce antigen-specific T reg .
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FOXP3 quantification might be a useful surrogate marker for the aggressive Sézary syndrome and serve as a prognostic marker for tumor progression. 
